GDC-4198

Key Takeaways

• GDC‑4198 targets CDK4 and CDK2 with low‑nanomolar potency
• Shows ~20‑fold selectivity for CDK4/6 over CDK6
• Demonstrated single‑agent activity after CDK4/6 therapy failure
• Early Phase 1/2 data target advanced breast cancer
• Developed by Regor, now owned by Genentech, presented at ACS 2026

Pulse Analysis

The CDK4/6 inhibitor class has become a cornerstone of hormone‑receptor‑positive breast cancer therapy, yet resistance inevitably emerges. Agents such as palbociclib, ribociclib and abemaciclib have demonstrated survival benefits, but tumor cells often bypass CDK4/6 blockade by up‑regulating CDK2 or activating alternative cyclin pathways. This therapeutic gap has spurred a wave of research into dual‑targeted inhibitors that can suppress both CDK4/6 and CDK2, aiming to restore cell‑cycle control in resistant disease.

GDC‑4198 distinguishes itself by delivering potent inhibition of CDK4 while simultaneously achieving low‑nanomolar activity against CDK2, a profile not common among existing agents. Its roughly 20‑fold selectivity over CDK6 reduces off‑target effects that can contribute to toxicity, potentially allowing higher dosing or longer treatment courses. Preclinical models suggest that concurrent CDK2 blockade can re‑sensitize tumors that have adapted to CDK4/6 inhibition, offering a mechanistic rationale for the observed single‑agent efficacy in patients previously treated with standard CDK4/6 drugs.

The ongoing Phase 1/2 trial, presented at the ACS Spring 2026 meeting, enrolls patients with advanced solid tumors, prioritizing breast cancer cohorts that have failed prior CDK4/6 therapy. If efficacy and safety benchmarks are met, GDC‑4198 could become a pivotal option for a sizable subset of refractory patients, bolstering Genentech’s pipeline and challenging competitors. Moreover, its dual‑target approach may set a new standard for next‑generation cyclin‑dependent kinase inhibitors, influencing future trial designs and combination strategies across oncology.